Director JOHNSON JOHN sold Xeris Biopharma Holdings ($XERS) shares on the open market twice in the last year for a total of $1.76 million, with the most recent sale on December 19, 2025; these sales rank 3,739th among insiders by value. He also sold Axogen ($AXGN) shares five times for $1.43 million total, most recently on December 9, 2025, ranking 4,146th. Across nearly 12,000 insiders with sales averaging 8.6 million and about six transactions each, JOHNSON JOHN made no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 19, 2025 | Xeris Biopharma Holdings, Inc. | $XERS | JOHNSON JOHN | Director | S | Common Stock | 135400 | $7.22 | 698,083.0000 | 177,617,307 | 16.25% | 0.08% |
| Dec. 8, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | S | Common Stock | 11802 | $31.26 | 13,141.0000 | 49,088,436 | 47.32% | 0.02% |
| Dec. 8, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | S | Common Stock | 11891 | $31.22 | 13,141.0000 | 49,088,436 | 47.50% | 0.02% |
| Dec. 9, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | S | Common Stock | 13141 | $29.98 | 0.0000 | 49,088,436 | 100.00% | 0.03% |
| Dec. 9, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | S | Common Stock | 8545 | $29.98 | 13,141.0000 | 49,088,436 | 39.40% | 0.02% |
| Dec. 9, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Common Stock | 8545 | $6.30 | 21,686.0000 | 49,088,436 | 65.03% | 0.02% |
| Dec. 8, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Common Stock | 11891 | $6.30 | 25,032.0000 | 49,088,436 | 90.49% | 0.02% |
| Dec. 9, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Stock Option (right to purchase) | 8545 | $0.00 | 0.0000 | 49,088,436 | 100.00% | 0.02% |
| Dec. 8, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Stock Option (right to purchase) | 11891 | $0.00 | 8,545.0000 | 49,088,436 | 58.19% | 0.02% |
| Aug. 13, 2025 | Xeris Biopharma Holdings, Inc. | $XERS | JOHNSON JOHN | Director | S | Common Stock | 107500 | $7.32 | 833,483.0000 | 146,772,758 | 11.42% | 0.07% |
| June 19, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | A | Restricted Stock Units | 14150 | $0.00 | 14,150.0000 | 44,257,754 | 9999.99% | 0.03% |
| June 9, 2025 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | S | Common Stock | 4073 | $10.61 | 24,943.0000 | 44,257,754 | 14.04% | 0.01% |
| June 4, 2025 | Xeris Biopharma Holdings, Inc. | $XERS | JOHNSON JOHN | Director | A | Common Stock | 50000 | $0.00 | 940,983.0000 | 146,772,758 | 5.61% | 0.03% |
| May 22, 2025 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | A | Common Stock | 8333 | $0.00 | 16,666.0000 | 54,173,000 | 100.00% | 0.02% |
| May 22, 2025 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 54,173,000 | 9999.99% | 0.02% |
| Dec. 19, 2024 | Applied Therapeutics, Inc. | $APLT | JOHNSON JOHN | Executive Chairman | A | Common Stock | 500000 | $0.00 | 500,000.0000 | 144,345,781 | 9999.99% | 0.35% |
| Dec. 19, 2024 | Applied Therapeutics, Inc. | $APLT | JOHNSON JOHN | Executive Chairman | A | Stock Option (Right to Buy) | 1000000 | $0.00 | 1,000,000.0000 | 144,345,781 | 9999.99% | 0.69% |
| Sept. 1, 2024 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Restricted Stock Units | 11904 | $0.00 | 0.0000 | 42,878,543 | 100.00% | 0.03% |
| Sept. 1, 2024 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Common Stock | 11904 | $0.00 | 29,016.0000 | 42,878,543 | 69.57% | 0.03% |
| June 18, 2024 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 26,832,000 | 9999.99% | 0.05% |
| June 18, 2024 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | A | Common Stock | 8333 | $0.00 | 8,333.0000 | 26,832,000 | 9999.99% | 0.03% |
| June 6, 2024 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | A | Common Stock | 10653 | $0.00 | 17,112.0000 | 42,878,543 | 164.93% | 0.02% |
| June 6, 2024 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | A | Employee Stock Option (right to purchase) | 18248 | $0.00 | 18,248.0000 | 42,878,543 | 9999.99% | 0.04% |
| June 5, 2024 | Xeris Biopharma Holdings, Inc. | $XERS | JOHNSON JOHN | Director | A | Common Stock | 50000 | $0.00 | 890,983.0000 | 137,674,857 | 5.95% | 0.04% |
| March 15, 2024 | Xeris Biopharma Holdings, Inc. | $XERS | JOHNSON JOHN | Director | J | Common Stock | 89571 | $0.00 | 840,983.0000 | 137,674,857 | 11.92% | 0.07% |
| March 18, 2024 | Xeris Biopharma Holdings, Inc. | $XERS | JOHNSON JOHN | Director | M | Stock Option (Right to Buy) | 215600 | $0.00 | 0.0000 | 137,674,857 | 100.00% | 0.16% |
| March 18, 2024 | Xeris Biopharma Holdings, Inc. | $XERS | JOHNSON JOHN | Director | M | Common Stock | 215600 | $1.99 | 751,412.0000 | 137,674,857 | 40.24% | 0.16% |
| March 11, 2024 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | D | Stock Option (right to buy) | 2300 | $0.00 | 0.0000 | 22,054,000 | 100.00% | 0.01% |
| March 11, 2024 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | A | Stock Option (right to buy) | 8549 | $0.00 | 8,549.0000 | 22,054,000 | 9999.99% | 0.04% |
| March 11, 2024 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | D | Stock Option (right to buy) | 2083 | $0.00 | 0.0000 | 22,054,000 | 100.00% | 0.01% |
| March 11, 2024 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | D | Stock Option (right to buy) | 2083 | $0.00 | 0.0000 | 22,054,000 | 100.00% | 0.01% |
| March 11, 2024 | Verastem, Inc. | $VSTM | JOHNSON JOHN | Director | D | Stock Option (right to buy) | 2083 | $0.00 | 0.0000 | 22,054,000 | 100.00% | 0.01% |
| Sept. 1, 2023 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | A | Restricted Stock Units | 11904 | $0.00 | 11,904.0000 | 42,083,125 | 9999.99% | 0.03% |
| Sept. 1, 2023 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | A | Stock Option (right to purchase) | 20436 | $0.00 | 20,436.0000 | 42,083,125 | 9999.99% | 0.05% |
| June 1, 2023 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Restricted Stock Units | 6459 | $0.00 | 0.0000 | 42,083,125 | 100.00% | 0.02% |
| June 1, 2023 | Axogen, Inc. | $AXGN | JOHNSON JOHN | Director | M | Common Stock | 6459 | $0.00 | 6,459.0000 | 42,083,125 | 9999.99% | 0.02% |